ArticleJournal of medicinal chemistry2020
Pyrrolo[2',3':3,4]cyclohepta[1,2-
Open access · hybridAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 53 citations in OpenAlex.
- Exploring marine-derived compounds as potential anti-cancer agents: Mechanisms and therapeutic implications.Cancer pathogenesis and therapy · 2026Review
- Pyrrolidine-based hybrid compounds: design, synthesis, in vitro and in vivo pharmacological properties and molecular docking studies.Future medicinal chemistry · 2025Article
- Tubulin inhibitors: an insight into new strategies to combat leukemia.Future medicinal chemistry · 2025Review
- Article
- A novel series of dipeptide derivatives containing indole-3-carboxylic acid conjugates as potential antimicrobial agents: the design, solid phase peptide synthesis,RSC advances · 2023Article
- Identification of pyrrolo[3',4':3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas.European journal of medicinal chemistry · 2023Article
- Synthetic Analogs of Marine Alkaloid Aplysinopsin Suppress Anti-Apoptotic Protein BCL2 in Prostate Cancer.Molecules (Basel, Switzerland) · 2022Article
- The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma.International journal of molecular sciences · 2022Article
- Novel insights on [1,2]oxazolo[5,4-e]isoindoles on multidrug resistant acute myeloid leukemia cell line.Drug development research · 2022Article
- Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2.Molecules (Basel, Switzerland) · 2022Article
- Recent Updates on Marine Cancer-Preventive Compounds.Marine drugs · 2021Review
- Marine Pyrrole Alkaloids.Marine drugs · 2021Review
- Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms.Marine drugs · 2021Review
- Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds.Topics in current chemistry (Cham) · 2021Review
- Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 3 countries.
Virginia SpanòDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Roberta RoccaNet4Science srl, Academic Spinoff, Università Magna Græcia di Catanzaro, Viale Europa, 88100 Catanzaro, Italy.ORCID 0000-0002-0680-7097
Marilia BarrecaDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Daniele GiallombardoDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Alessandra MontalbanoDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.ORCID 0000-0002-8891-598X
Anna CarboneDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Maria Valeria RaimondiDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Eugenio GaudioInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland.
Roberta BortolozziIstituto di Ricerca Pediatrica IRP, Fondazione Città della Speranza, Corso Stati Uniti 4, 35127 Padova, Italy.
Ruoli BaiScreening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
Pierfrancesco TassoneDipartimento di Medicina Sperimentale e Clinica, Università Magna Græcia di Catanzaro, Viale Europa, 88100 Catanzaro, Italy.
Stefano AlcaroDipartimento di Scienze della Salute, Università Magna Græcia di Catanzaro, Viale Europa, 88100 Catanzaro, Italy.
Ernest HamelScreening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
Giampietro ViolaIstituto di Ricerca Pediatrica IRP, Fondazione Città della Speranza, Corso Stati Uniti 4, 35127 Padova, Italy.
Francesco BertoniInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland.
Paola BarrajaDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.
University of Palermo · ITInstitute of Oncology Research · CHMagna Graecia University · ITNational Institutes of Health · USCittà della Speranza Foundation · ITUniversity of Padua · IT
Funding
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
Abstract
A new class of pyrrolo[2',3':3,4]cyclohepta[1,2-
Indexed as
Antimitotic AgentsAntineoplastic AgentsApoptosisCell ProliferationCells, CulturedDose-Response Relationship, DrugDrug Screening Assays, AntitumorG2 Phase Cell Cycle CheckpointsHeLa CellsHumansMitosisModels, MolecularMolecular StructureOxazolesStructure-Activity RelationshipAntimitotic AgentsAntineoplastic AgentsOxazoles
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.